{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-267696","form_type":"8-K","ticker":"RVMD","cik":"0001628171","company_name":"Revolution Medicines, Inc.","filed_at":"2023-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.836224+00:00","generated_at":"2026-06-09T02:43:32.992452+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Revolution Medicines sets final merger exchange ratio at 0.1112; ISS/Glass Lewis back deal","bullets":["Final exchange ratio: 0.1112 RVMD shares per EQRx share, up from illustrative 0.0734.","ISS and Glass Lewis recommend RVMD stockholders vote FOR the share issuance.","Merger expected to add ~$1.1B net cash (~$20 per share issued); close targeted Nov 2023.","RVMD to issue ~55M shares (excl. warrants/earn-outs) for the acquisition.","RVMD special meeting of stockholders scheduled for November 8, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-267696","json":"https://secwatch.observer/filing/0001193125-23-267696.json","markdown":"https://secwatch.observer/filing/0001193125-23-267696.md","text":"https://secwatch.observer/filing/0001193125-23-267696.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628171/000119312523267696/0001193125-23-267696-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628171/000119312523267696/d527979d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T02:43:32.992452+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}